CORRECTION

Correction to: An Evaluation of Malaysian Regulatory Process for New Active Substances Approved in 2017 Using the OpERA Methodology

Noraisyah Mohd Sani, MSc, B. Pharmacy (Hon)¹ · Neil McAuslane, PhD² · Siti Hidayah Kasbon, MSc, B. Pharmacy (Hon)¹ · Rosilawati Ahmad, MSc, B. Pharmacy (Hon)¹ · Faridah Aryani Md. Yusof, PhD, MSc, B. Pharmacy (Hon)¹ · Prisha Patel, MSc²

Published online: 9 April 2020

© The Drug Information Association, Inc 2020

Correction to: Therapeutic Innovation & Regulatory Science
<https://doi.org/10.1007/s43441-020-00140-4>

The authors have revised Fig. 1. The revised Fig. 1 is presented below.

The original article can be found online at <https://doi.org/10.1007/s43441-020-00140-4>.

✉ Neil McAuslane
nmcauslane@cirscl.org

¹ National Pharmaceutical Regulatory Agency, Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia

² Centre for Innovation in Regulatory Science (CIRS), 160 Blackfriars Road, London SE18EZ, UK

Figure 1. NPRA Review Process.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.